Latest Breaking News On - Claudine prowse - Page 1 : comparemela.com

Posted on 344 Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today reports financial and operational results for the fourth quarter and year ended December 31, as well as guidance for anticipated 2021 milestones. “2021 is poised to be another exciting year for Rocket,” said Gaurav Shah, M.D., Chief Executive Officer of Rocket. “We anticipate clinical data from all five of our gene therapy programs, initiation of our first in-house AAV cGMP production from our new manufacturing facility, and continued strengthening of our organization, manufacturing capabilities and infrastructure. We look forward to continued validation of our gene therapy platforms with updated results from registrational studies in FA and LAD-I, longer term findings in Danon Disease and PKD, and clinical proof-of-concept for

United statesNew jerseyLos angelesCity ofUnited kingdomGaurav shahClaudine prowseCarlos garcia paradaKinnari patelUniversity of californiaCalifornia institute for regenerative medicineAmerican society of hematology annual meetingStrategy corporate developmentFanconi anemia research fundRocket pharmaceuticals incUniversity of colorado